Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
B
Babel, Heiko
AbbVie Inc.
(
M-009
)
Combined multi-analyte population PK modeling of ABBV-400, a novel c-Met targeting ADC
Heiko Babel
Favorite
Bajaj, Gaurav
Genmab
(
W-004
)
Development of QSP model of non-small cell lung cancer and its application to support optimal dose selection for acasunlimab, a bispecific antibody targeting 4-1BB and PD-L1
Gaurav Bajaj
Favorite
(
W-005
)
Utilizing PBPK/RO model for description of GEN1042 (BNT312) PK and prediction of trimer level to guide dose selection
Gaurav Bajaj
Favorite
(
W-006
)
Application of identifiability analysis to obtain reliable parameters of the QSP model describing mechanism of action GEN1042 (BNT312) and acasunlimab
Gaurav Bajaj
Favorite
Baron, Kyle
Metrum Research Group
(
W-007
)
Simulating Adaptive Dosing Regimens from PK and PKPD Models Using mrgsolve
Kyle Baron
Favorite
Barua, Dipak
Translational Disease Modeling, Translational Medicine and Early Development, Sanofi R&D, Cambridge, US
(
M-010
)
Quantitative system pharmacology model for tri-specific HER2xCD3xCD28 T-Cell Engager SAR443216
Dipak Barua
Favorite
Bedathuru, Dinesh
Vantage Research
(
T-009
)
Development of QSP platform model for predicting clinical efficacy and CRS incidence of CD3 bispecifics in STEAP1 Prostate Cancer
Dinesh Bedathuru
Favorite
(
T-010
)
A quantitative systems pharmacology model framework for combined clinical efficacy and hematological toxicity predictions for antibody drug conjugates
Dinesh Bedathuru
Favorite
Bender, Brendan
Genentech, Inc.
(
T-011
)
A multi-stage modeling approach towards predicting cytokine release syndrome (CRS) in patients receiving Mosunetuzumab
Brendan Bender
Favorite
Bergstrand, Martin
Pharmetheus AB
(
W-008
)
The reference corrected VPC (rcVPC) - An informative model diagnostic for assessing underlying exposure-response relationships
Martin Bergstrand
Favorite
Bewernitz, Michael
US Food and Drug Administration
(
M-011
)
A Survey of Model Informed Approaches in Neuroscience Drug Development
Michael Bewernitz
Favorite
Bhagwat, Sharvari
Inhibrx Inc
(
M-035
)
PK/PD Characterization of INBRX-140, a Novel anti-FcRn x anti-albumin bispecific antibody
Sharvari Bhagwat
Favorite
Bhattacharya, Souvik
Astellas Pharma
(
M-012
)
Considerations for Industry—Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting Program
Souvik Bhattacharya
Favorite
Bishop, Corey
Clinical Pharmacology and Pharmacometrics Johnson & Johnson
(
T-012
)
popPK & ER analysis of amivantamab in combination with chemotherapy for the treatment of patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer after osimertinib failure
Corey Bishop
Favorite
Boivin-Champeaux, Clémence
University of Florida
(
M-013
)
Development of a quantitative systems pharmacology model for Hepatitis B Virus infection and Hepatitis D virus co-infection.
Clémence Boivin-Champeaux
Favorite
Bose, Maitreyee
Amgen
(
T-013
)
A hybrid semi-mechanistic and machine learning framework to predict Cytokine Release Syndrome following T-cell engaging immunotherapies
Maitreyee Bose
Favorite
Bottino, Dean
Takeda Development Center America
(
W-010
)
Modeling the evolution of activation marker distributions in flow cytometry data representing cell populations in patients dosed with immunomodulating agents
Dean Bottino
Favorite
Bozenhardt, Emily
J&J Innovative Medicine
(
T-014
)
Longitudinal Population Pharmacokinetic/Pharmacodynamic Modeling of Continuous Efficacy Endpoint and Biomarker for a Novel Compound
Emily Bozenhardt
Favorite
Braniff, Nathaniel
Pfizer
(
T-015
)
A quantitative systems pharmacology model to explore resistance mechanisms and combination strategies in ALK+ NSCLC targeted therapies
Nathaniel Braniff
Favorite
Brizzi, Francesco
Predictive Modelling and Data Analytics, Roche Pharma Research & Early Development, Roche Innovation Center Basel, Switzerland
(
T-016
)
Bridging the Gap: A Comprehensive Checklist for Hybrid Pharmacometrics-Machine Learning Model Building to Support Oncology Clinical Development
Francesco Brizzi
Favorite
Budak, Maral
University of Michigan
(
M-014
)
A systematic efficacy analysis of multidrug therapies for tuberculosis using a multi-scale agent-based model
Maral Budak
Favorite
Buyukozturk, Fulden
MathWorks
(
T-017
)
Application of an advanced gut PBPK model to characterize intestinal transport and P-glycoprotein-mediated drug-drug interaction: a case study with Digoxin and Clarithromycin
Fulden Buyukozturk
Favorite
Byrne, Rena
Metrum Research Group
(
W-011
)
Data Gaps, Model Mishaps: Quantifying the Impact of Missing Pharmacometrics Data on Pharmacodynamic Projections
Rena Byrne
Favorite
